PLC对人血小板GPIb的作用

目的 应用竞争性酶联免疫定量检测磷酯酶C(PLC)对人血小板膜糖蛋白Ib(GPIb)量的变化,探讨用药后抑制血小板粘附作用的机制。方法 用竞争性酶联免疫药盒测定并绘制标准曲线图;取健康人血制备洗涤血小板,将其分为4组:①生理盐水组;②PLC 0.5 U组;③PLC 1.0U组;④PLC 2.0 U组,分别替代药盒中标准IgG(IgG-ST)进行实验,酶标仪上测OD_(492)值,共实验6人次,依据OD_(492)值在标准曲线图和Eocel软件求出GPIb的量及 用t值检测它们之间的相关性。结果 用生理盐水、PLC0.5 U、1.0 U和 2.0 U组的OD_(492)值和GPIb数量(ng)分别为0.768±0.078、1.103±0.118、1.367±0.102、2.055±0.453和134.669±13.144、101.838±9.879、82.632±5.354、73.183±14.740。PLC 1.0 U和2.0 U组与生理盐水组比差异有显著性(P<0.01),而其它各组之间比差异无显著性(P>0.05)。结论 PLC减少GPIb的量,从而抑制血小板粘附性,这也可能是PLC抗血小板聚集作用的重要原因之一。

Effect of PLC on human platelet membrane glycoprotein Ib

AIM To explore mechanism of PLC inhibition on platelet adhesion by quantitive determination of PLC influence on human platelet membrane GPIb quantity (ng) with competitive enzyme-linked immunosorbent assay (CELISA). METHODS Standard curve are drawn with CELISA kit. Washing platelet are made from healthy human blood and divided into four parts: (1)physiological saline part;(2)PLC 0. 5 U part; (3)PLC 1. 0 U part; (4)PLC 2. 0 U part to replace standard IgGCIgG-5T). Then OD492 are tested with TECAN. The experiment was made for 6 times. GPIb quantity(ng) was calculated according to OD492 by standard curve and Eocel. Their correlation are tested with t value. RESULTS OD492 of physiological saline, PLC 0. 5 U, 1.0 U, 2. 0 U were 0.768 ± 0.078, 1.103±0.018, 1.367 ± 0.102, 2.055 ± 0.453 respectively, and their corresponding GPIb quantities (ng) are 134.669 ± 13.144, 101.838 ± 9.879, 82.632 ± 5.354, 73. 183?±14. 74 respectively. The differences of GPIb quantities are significant a-mong PLC 1. 0 U , PLC 2. 0 U and physiological saline ( P < 0. 01), but not notable among other parts(P>0. 05). CONCLUSION PLC can reduce platelet membrane GPIb quantity apparently, so it can inhibit platelet adhesion. It may be one of the important reasons of PLC anti-aggregation on platelet.